By unveiling that miR-21 abrogation, together with FXR activation by OCA, significantly improves whole body metabolic parameters in NASH, our results highlight the therapeutic potential of nuclear receptor multi-targeting therapies for NAFLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.